• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可延长QT间期的钙通道阻滞剂。

Calcium channel blockers that prolong the QT interval.

作者信息

Somberg J C

出版信息

Am Heart J. 1985 Feb;109(2):416-21. doi: 10.1016/0002-8703(85)90628-3.

DOI:10.1016/0002-8703(85)90628-3
PMID:3871300
Abstract

The development of a group of calcium channel blockers that prolong the QT interval has raised interest in their possible proarrhythmic potential. In animal experiments lidoflazine has no observed arrhythmogenic potential and no antiarrhythmic potential in a model sensitive to the antiarrhythmic properties of both conventional and investigational agents. This lack of antiarrhythmic potential reduces the possible proarrhythmic potential even further, since it has been my observation that many of the more potent antiarrhythmic agents may facilitate arrhythmias in a considerable percentage of the most severely ill patients. Bepridil has both slow channel blocking properties and fast channel blocking effects and thus possesses an antiarrhythmic effect beyond the prolongation of repolarization. Even though early studies with humans showed the drug to be no more effective than the conventional reference agent procainamide, its potential cannot be fully assessed by these preliminary studies. The assessment of arrhythmogenicity is determined by use of the technique of PES. This technique has been shown effective in identifying patients with electrical instability and in identifying the effectiveness of antiarrhythmic agents in preventing VT and sudden death. Thus it seems probable that PES studies may be effective in predicting which drug or agent would facilitate arrhythmias. Alcohol, caffeine, cigarette smoke, and catecholamines facilitate PES induction of VT, lending support to the hypothesis that PES studies can be used to identify proarrhythmic drugs. In fact, patients who experience cardiac arrest on a class I agent can have VT provoked on that agent but not on antiarrhythmic drug therapy. PES thus identifies the proarrhythmic effect of the drug in that particular patient.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

一类可延长QT间期的钙通道阻滞剂的出现,引发了人们对其致心律失常潜在可能性的关注。在动物实验中,利多氟嗪在对传统药物和研究性药物的抗心律失常特性敏感的模型中,未观察到有致心律失常的可能性,也没有抗心律失常的作用。这种缺乏抗心律失常作用的情况,进一步降低了其致心律失常的潜在可能性,因为据我观察,许多效力更强的抗心律失常药物可能会在相当比例的重症患者中促发心律失常。苄普地尔兼具慢通道阻滞特性和快通道阻滞作用,因此除了延长复极外还具有抗心律失常作用。尽管早期人体研究表明该药物并不比传统参比药物普鲁卡因胺更有效,但这些初步研究并不能完全评估其潜力。致心律失常性的评估通过程序电刺激(PES)技术来确定。该技术已被证明在识别电不稳定患者以及确定抗心律失常药物预防室性心动过速和心脏性猝死的有效性方面有效。因此,PES研究似乎有可能有效预测哪种药物或制剂会促发心律失常。酒精、咖啡因、香烟烟雾和儿茶酚胺会促进PES诱发室性心动过速,这支持了PES研究可用于识别致心律失常药物的假说。事实上,在使用I类药物时发生心脏骤停的患者,使用该药物可诱发室性心动过速,但抗心律失常药物治疗时则不会。因此,PES可识别该特定患者中药物的致心律失常作用。(摘要截选至250词)

相似文献

1
Calcium channel blockers that prolong the QT interval.可延长QT间期的钙通道阻滞剂。
Am Heart J. 1985 Feb;109(2):416-21. doi: 10.1016/0002-8703(85)90628-3.
2
Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.钾通道与钙通道联合阻断活性作为抗心律失常疗效的基础且致心律失常风险较低:BRL-32872的实验概况
J Pharmacol Exp Ther. 1996 Feb;276(2):637-46.
3
The effect of bepridil, verapamil, and quinidine in the prevention of ventricular tachycardia induced by programmed electrical stimulation in the digitalized dog.苄普地尔、维拉帕米和奎尼丁在预防洋地黄化犬程控电刺激诱发室性心动过速中的作用。
Am Heart J. 1984 Nov;108(5):1236-43. doi: 10.1016/0002-8703(84)90747-6.
4
Prolongation of QT interval and antiarrhythmic action of bepridil.
Am Heart J. 1985 Jan;109(1):19-27. doi: 10.1016/0002-8703(85)90410-7.
5
Electrophysiologic and antiarrhythmic properties of bepridil.
Am J Cardiol. 1985 Mar 15;55(7):59C-62C. doi: 10.1016/0002-9149(85)90808-2.
6
QT prolongation and arrhythmia suppression.QT间期延长与心律失常抑制。
Am Heart J. 1985 Feb;109(2):411-5. doi: 10.1016/0002-8703(85)90627-1.
7
Comparative electrophysiologic profiles of calcium antagonists with particular reference to bepridil.
Am J Cardiol. 1985 Mar 15;55(7):14C-19C. doi: 10.1016/0002-9149(85)90800-8.
8
Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo.新型联合离子通道阻滞剂AZD1305与多非利特在甲氧明致敏兔体内的离子通道阻断特性及其促心律失常潜力评估。
J Cardiovasc Pharmacol. 2009 Jul;54(1):82-9. doi: 10.1097/FJC.0b013e3181ac62c9.
9
Antiarrhythmic drug efficacy at electrophysiology testing: predictive effectiveness of procainamide and flecainide.抗心律失常药物在电生理检查中的疗效:普鲁卡因胺和氟卡尼的预测有效性
Am Heart J. 1986 Apr;111(4):632-8. doi: 10.1016/0002-8703(86)90090-6.
10
Comparison of verapamil and bepridil, two slow channel inhibitors, in protection against calcium-induced arrhythmias.
Naunyn Schmiedebergs Arch Pharmacol. 1986 Sep;334(1):105-9. doi: 10.1007/BF00498747.

引用本文的文献

1
Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.心脏安全药理学中的微电极阵列:一种研究QT间期延长的新工具。
Drug Saf. 2004;27(11):763-72. doi: 10.2165/00002018-200427110-00002.
2
QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.QT间期延长药物:其致心律失常风险的机制及临床相关性
Cardiovasc Drugs Ther. 1991 Apr;5(2):515-30. doi: 10.1007/BF03029779.